Is the watch-and-wait strategy suitable for every patient who has achieved a complete clinical response with neoadjuvant treatment in locally advanced rectum cancer?
- PMID: 38031877
- DOI: 10.1002/jso.27537
Is the watch-and-wait strategy suitable for every patient who has achieved a complete clinical response with neoadjuvant treatment in locally advanced rectum cancer?
Keywords: clinical complete response; pathological complete response; rectum cancer; watch-and-wait strategy.
References
REFERENCES
-
- Conroy T, Bosset JF, Etienne PL, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:702-715. doi:10.1016/S1470-2045(21)00079-6
-
- You YN, Hardiman KM, Bafford A, et al. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of rectal cancer. Dis Colon Rectum. 2020;63:1191-1222. doi:10.1097/DCR.0000000000001762
-
- Hiotis SP, Weber SM, Cohen AM, et al. Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients. J Am Coll Surg. 2002;194:131-135.
-
- discussion 135-136. doi:10.1016/s1072-7515(01)01159-0
-
- Smith FM, Chang KH, Sheahan K, Hyland J, O'Connell PR, Winter DC. The surgical significance of residual mucosal abnormalities in rectal cancer following neoadjuvant chemoradiotherapy. Br J Surg. 2012;99:993-1001. doi:10.1002/bjs.8700
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
